A Study to Assess the Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP
Status:
Active, not recruiting
Trial end date:
2022-10-26
Target enrollment:
Participant gender:
Summary
This study will assess the ability of eltrombopag to induce sustained treatment-free
remission in ITP subjects who relapsed or failed to respond to an initial treatment with
steroids.
There is limited, mainly retrospective evidence that earlier use of eltrombopag after ITP
diagnosis, will allow a larger proportion of subjects to achieve sustained remission after
tapering off drug. Clinically there is a need for a less toxic regimen that will provide
responses and sustained remission with a shorter treatment interval. This trial is designed
to assess this.